E. Bonmassar
Sapienza University of Rome
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by E. Bonmassar.
Cancer Treatment Reviews | 2013
Francesco Torino; E. Bonmassar; Laura Bonmassar; Liana De Vecchis; Agnese Barnabei; Cecilia Zuppi; Ettore Capoluongo; Angelo Aquino
The availability of sensitive methods has allowed the detailed study of circulating tumor cells only recently. Evolving evidence support the prognostic and predictive role of these cells in patients affected by several solid tumors, including colorectal cancer. Ongoing studies are aimed at confirming that the molecular characterization of circulating tumor cells in peripheral blood and in bone marrow of patients is a powerful tool to improve the patient risk-stratification, to monitor activity of the drugs, to develop more appropriate targeted therapies and tailored treatments. In parallel, results from these correlative studies promise to gain a better biological understanding of the metastatic process. The clinical utility of the detection of circulating tumor cells in patients affected by colorectal cancer is still hampered by a number of specific hurdles. Improvement in sensitivity and specificity of the available methods of detection, standardization of these methods and functional characterization of circulating tumor cells in well designed and statistically well powered studies are the key steps to reach these ambitious objectives in colorectal cancer patients as well.
Cancer Immunology, Immunotherapy | 1984
B. Nardelli; Paolo Puccetti; Luigina Romani; Gianni Sava; E. Bonmassar; Maria C. Fioretti
SummaryEquitoxic doses of 5-(3-3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) and aryl-triazene derivatives (compounds all capable of inducing a marked increase in murine tumor cell immunogenicity) were studied for their effects on the host immune system. At different times after drug exposure the animals were tested for allograft responses, competence in producing lymphocytes active in lethal graft-versus-host disease, delayed-type hypersensitivity, humoral antibody production, and mitogen responsiveness. While some of the aryl-triazenes tested (DM-COOK DM-NO2) showed a pattern of immunodepression similar to that of DTIC, others were less (MIC, MM-COOK, MM-Cl) or far less (DM-Cl, MM-NO2) active than DTIC in impairing host immunocompetence, although all retained or even augmented their ability to induce chemical xenogenization.
Leukemia Research | 1985
L. De Vecchis; Grazia Graziani; Beatrice Macchi; C. Grandori; Simonetta Pastore; M. Popovic; R.C. Gallo; E. Bonmassar
Cell-mediated natural cytotoxicity (CMNC) of fresh or long-term cultured lymphocytes collected from HTLV-positive patients or infected in vitro with the virus, was tested against K562 target cells. Severe depression of reactivity was found in fresh lymphocytes of three patients with advanced disease, in 12 in vitro established T-cell malignant lines, and two HTLV-infected cord blood (C5/MJ and C91/PL) lines. Moreover, all (eight) HTLV-1 infected cell lines listed showed a significant inhibition of CMNC of peripheral blood lymphocytes of healthy donors. Whether virus infection promotes the outgrowth of pre-existing suppressor cells and/or produce changes of the T-lymphocyte function is unknown.
Cancer Immunology, Immunotherapy | 1990
Chiara D'Onofrio; Caterina Pesce; Tecla Fontana; Fabrizio Ciprani; E. Bonmassar; R. Caliò
SummaryInfection with human T-cell leukemia virus type I (HTLV-I) is associated in vitro and in vivo with a remarkable depression of cell-mediated immune functions. In the present report it is shown that early events following virus-induced suppression of the cell-mediated immune response of freshly isolated cord blood mononuclear cells (CBL) infected with HTLV-I can be partially counteracted by treatment with interferons α, β or γ (IFN). All three types of IFN exerted a protective effect on CBL cultures exposed to the virus. This resulted in: (a) a reduced number of virus-positive cells until 4 weeks of culture; (b) delay in the clonal expansion of infected cells (IFNα and γ); (c) increased natural killer cell activity of CBL, 1 week post-infection (p.i.), mediated by IFNγ; (d) increase of allospecific recognition of infecting and priming HTLV-I donor MT-2 cells by CBL in a cytotoxic-T-lymphocyte-like response, mediated by IFN and particularly by IFNγ; (e) phenotype distribution of CBL subpopulations, tested 4 days p.i., more similar to that of non-infected CBL cultures.In contrast, the overall CBL proliferation, that is profoundly depressed during the first week p.i., was not restored by IFN treatments, suggesting that boosting of the cell-mediated killing induced by IFN might involve the maturation of undifferentiated precursor cells rather than stimulation of their proliferation. The improvement of the efficiency of the antiviral immune response induced by treatment with IFN is likely to contribute to the clearance of virus-positive cells during the early phase of infection. This would provide experimental evidence to support an immunopharmacological approach contributing to the conversion of HTLV-I carriers from positive to negative.
Journal of Chemotherapy | 2001
Salvatore P. Prete; A. Giuliani; E. Iona; L. Fattorini; G. Orefici; Ornella Franzese; E. Bonmassar; Grazia Graziani
Abstract Non-peptide antigens (e.g. glycolipids of microbial origin) presented by monocyte-associated CD1 molecules to T cells appear to play an important role in host immunity against tuberculosis and other pathogenic bacteria. Since vaccination with Bacillus Calmette-Guerin (BCG) has limited efficacy, the influence of viable BCG organisms on the induction of CD1b antigen by granulocyte macrophage-colony stimulating factor (GM-CSF) has been tested in adherent mononuclear cells obtained from peripheral blood of healthy donors. The results indicate that the vaccine reduces substantially CD1b induction by GM-CSF. On the other hand, BCG was found to promote a slight increase in the expression of this molecule on target cells not exposed to GM-CSF. Attempts to reverse the antagonistic effects of BCG on GM-CSF with high concentrations of GM-CSF, alone, or associated with IL-4, were unsuccessful. Moreover, mycobacteria suppression by 10 μmg/ml of rifampin, did not affect BCG influence on CD1b induction. The present results suggest that mycobacterium-induced impairment of the CD1 system could play a role in the unsatisfactory results obtained with BCG vaccination.
Pharmacological Research | 1990
Beatrice Macchi; Chiara D'Onofrio; Rosario A. Labianca; E. Bonmassar
Human mononuclear cells derived from peripheral blood of adult donors (PBMC) or from neonatal cord blood (CBMC) were found to be equally sensitive to the protective effect of alpha- and beta-interferons (IFNs) against the infection with HTLV-I during long-term culture. The effect of IFNs was evidenced by a remarkable reduction of the number of virus-positive cells during culture as evaluated by indirect immunofluorescence for the p19 virus core protein. Moreover, the appearance of p19-positive immortalized clones was inhibited by IFNs in PBMC co-cultures, whereas it was delayed in CBMC cultures. These kinetics are in relation with the higher permissivity of CBMC to the virus in comparison with PBMC, since in CBMC cultures infected cells can be clearly detected starting already 1 week post-infection (p.i.), whereas in PBMC cultures their appearance time is approximately at the 6th week p.i. IFNs acted by priming PBMC and CBMC to an active antiviral competence, since one single treatment with 1000 IU/ml of alpha- or beta-IFN at the onset of the co-culture of mononuclear cells with irradiated virus-donor cells was able to maintain very low levels of infection for approximately 6 weeks in CBMC cultures and at least for 18 weeks in PBMC cultures. As a consequence, it seems likely that IFN action is mediated by the expression of a defined, although not completely identified, set of genes in the host cells.
Cancer Immunology, Immunotherapy | 1988
Stefania D'Atri; Maria Pia Fuggetta; Gabriella Giganti; Lucio Tentori; Mario Roselli; Corrado Nunziata; Simonetta Pastore; E. Bonmassar; Liana De Vecchis
SummaryA good correlation was found between in vivo and in vitro responses of peripheral MNC from breast cancer patients and the NK boosting effect of human βIFN. In vitro immunochemotherapy studies showed that marked antitumor effects were obtained against cultured cancer cells when a widely used chemotherapeutic agent such as 5-FU was combined with nonsensitized spontaneously cytolytic MNC, preactivated in vitro with βIFN. These results suggest that the in vitro susceptibility assay of MNC to IFNs could be used for predicting favorable responses to immunochemotherapy regimens employing IFNs as immunomodulating agents.
Cancer Immunology, Immunotherapy | 1987
Lucio Tentori; Maria Pia Fuggetta; Stefania D'Atri; Angelo Aquino; Corrado Nunziata; Mario Roselli; Paolo Ballatore; E. Bonmassar; Liana De Vecchis
SummaryThe present study was designed to test whether immunomodulating doses of human beta-interferon would affect the natural cell-mediated cytotoxic function in untreated breast cancer patients or in those subjected to antitumor therapy. Analyses were performed on 11 breast cancer patients, 3 at stage 1 and 8 at stage 2, the latter being subjected to cyclophosphamide, methotrexate, 5-Fluorouracil (CMF) adjuvant chemotherapy. Five patients treated with CMF and 3 patients not subjected to adjuvant chemotherapy, received human beta-interferon (IF, 2×106 IU/patient, i.m.), on days 0,7, and 15 for 6 cycles of 31 days each. The natural killer (NK) activity (NKA) of peripheral blood mononuclear cells (MNC) was tested 24 and 48 h after low-dose IF administration. The results of NKA determinations carried out for the 6 cycles of treatment show that (1) chemotherapy alone depressed NKA; (2) IF alone increased NKA in stage 1 patients not treated with CMF; (3) IF antagonized the depressive activity of CMF on NK function and significantly augumented NKA in the case of low “basal” cytotoxic activity detectable in MNC collected before IF administration.Parallel in vitro studies showed that the inhibitory effect on NKA provoked by CMF is due to cyclophosphamide present in the association and is effectively antagonized by IF. These data provide rational bases for using IF in immunochemotherapy regimens, when tumor cells are supposed to be susceptible to host control by the natural resistance function.
Journal of Chemotherapy | 2001
Ornella Franzese; A. Comandini; A. Lombardi; A. Saponiero; E. Bonmassar
Abstract The present study describes the effect of the HIV protease inhibitor saquinavir on telomerase activity and interferon-γ (IFN-γ) production of non-adherent mononuclear cells (NA-MNC). Cells obtained from peripheral blood of healthy donors were exposed in vitro to a mixture of monoclonal antibodies against CD3 and CD28 membrane antigens in order to activate prevalently T cell subsets. Treatment with saquinavir was performed at the time of cell stimulation. Thereafter, NA-MNC were tested for telomerase activity (TRAP assay) and interferon-γ production up to 7 days later. The results show that saquinavir up-regulates telomerase activity and IFN-γ release in activated NA-MNC. These observations suggest that the anti-HIV effects of saquinavir could be accompanied by other immunopharmacological properties, influencing some aspects of the functional activity of immunocompetent cells. These include possible antagonistic effects against lymphocyte senescence, through telomerase activation, and a potentiating activity on the production of IFN-γ following T cell activation.
Journal of Chemotherapy | 2000
Angelo Aquino; Salvatore P. Prete; Susanne Baier; Daniela Cappelletti; J. W. Greiner; L. De Vecchis; Grazia Graziani; E. Bonmassar
Abstract Staurosporine (ST), a protein kinase C inhibitor, was found to produce anti-tumor effects against C22.20, a clonal subline derived from colon cancer HT-29 line, selected for low expression of carcinoembryonic antigen (CEA). However, as assessed by FACS analysis using propidium iodide, no apoptosis or cell cycle alteration was found on day 3 after treatment of C22.20 cells with ST (1-100nM). Exposure of cells to graded concentrations of the drug (i.e., from 1 to 25nM) resulted in a concentration-dependent increase in the percentage of CEA positive cells, as determined by flow cytometric analysis. However, when higher concentrations (i.e. 50nM - 100nM) of ST were used, the percentage of CEA positive cells declined compared to that detected in 25nM-treated tumor. Since these results were obtained in a clonal cell population, it is reasonable to hypothesize that induction rather than selection mechanism is involved in this phenomenon. The potential clinical interest of the present findings stems from the consideration that treatment with ST or its derivatives could improve sensitivity and efficacy of diagnostic and/or immunotherapeutic approaches based on CEA molecules.